Design Therapeutics Pushes Back Key Trial Timeline as Cash Burns
Design Therapeutics reported a net loss of $20.2 million for the second quarter of 2026 as it delayed guidance on its lead Friedreich's ataxia trial to late 2026 and early 2027.
Design Therapeutics (DSGN) reported a net loss of $20.2 million, or $(0.32) a share, for the second quarter of 2026, up from $19.1 million a year earlier. The clinical-stage biotechnology company, which is developing small-molecule therapies for genetically defined diseases, also disclosed a change to the timing of data from its lead RESTORE-FA trial that pushes a previously guided window into next year.
The company had told investors across three straight quarters — the first quarter of 2026 and the fourth and third quarters of 2025 — to expect RESTORE-FA data updates in the second half of 2026. The anchor release specifies a registrational-plan update in the fourth quarter of 2026 and 12-week dosing data in the first quarter of 2027, a narrower but later timeline than previously communicated. The release also newly defined the trial's primary efficacy endpoint as the percent change from baseline in endogenous blood FXN protein, alongside plans to test a dose level above 1 mpk, details absent from prior-quarter disclosures.
Total operating expenses rose to $22.2 million from $21.6 million a year earlier, a roughly 3% increase, as research and development spending climbed to $16.4 million from $15.7 million. R&D costs held mostly flat sequentially against the $14.6 million reported for the third quarter of 2025, while general and administrative expenses were unchanged year-over-year at $5.8 million but higher than the $4.7 million recorded in the third quarter of 2025. For the six months ended June 30, net loss reached $37.8 million, up 2.7% from $36.8 million in the same period of 2025, even as six-month R&D expense edged down to $30.8 million from $31.1 million.
Per-share losses narrowed slightly to $(0.32) from $(0.34) despite the wider dollar loss, a result of the weighted-average share count rising roughly 10% to 62.5 million shares from 56.9 million.
Cash, cash equivalents and investment securities fell to $207.4 million at June 30, 2026 from $222.8 million at March 31, a sequential decline of about $15.4 million, and from $219.8 million at the end of 2025. The trailing four quarters show a net decline of roughly $8.9 million in the cash position despite an interim rebound in the fourth quarter of 2025 and first quarter of 2026. Total stockholders' equity fell in step, dropping to $201.9 million at June 30 from $212.5 million at the end of 2025, a decline of about 5% over two quarters.
Design Therapeutics also reported progress on its DM1 program: dosing began in the Phase 1 multiple-ascending dose trial of DT-818, moving past prior guidance across the first quarter of 2026 and the fourth and third quarters of 2025 that such dosing was merely expected to start in the first half of 2026.